.

Browsing by Author "Sun, Charlotte"

LAUR Repository

Browsing by Author "Sun, Charlotte"

Sort by: Order: Results:

  • Borderline Resectable Pancreatic Cancer 
    Katz, Matthew; Pisters, Peter; Evans, Douglas; Sun, Charlotte; Lee, Jeffrey; Fleming, Jason; Vauthey, Jean-Nicolas; Abdalla, Eddie; Crane, Christopher (2015-11-17)
    Background Patients with borderline resectable pancreatic adenocarcinoma (PA) include those with localized disease who have tumor or patient characteristics that preclude immediate surgery. There is no optimal treatment ...
  • Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma 
    Raut, Chandrajit; Tseng, Jennifer; Sun, Charlotte; Wang, Huamin; Wolff, Robert; Crane, Christopher; Vauthey, Nicolas; Abdalla, Eddie; Lee, Jeffrey; Pisters, Peter; Evans, Douglas (2015-11-16)
    Objective: To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma. Summary Background ...
  • Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma 
    Katz, Matthew; Wang, Huamin; Fleming, Jason; Sun, Charlotte; Hwang, Rosa; Wolff, Robert; Varadhachary, Gauri; Abbruzzese, James; Crane, Christopher; Krishnan, Sunil; Vauthey, Jean-Nicolas; Abdalla, Eddie; Lee, Jeffrey; Pisters, Peter; Evans, Douglas (2015-11-17)
    Introduction Actual 5-year survival rates of 10–18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of multimodality therapy was uncommon in these series. We evaluated long-term ...
  • Pancreaticoduodenectomy with vascular resection 
    Abdalla, Eddie; Tseng, Jennifer; Raut, Chandrajit; Lee, Jeffrey; Pisters, Peter; Vauthey, Nicolas; Gomez, Henry; Sun, Charlotte; Crane, Christopher; Wolff, Robert; Evans, Douglas (2015-11-11)
    Major vascular resection performed at the time of pancreaticoduodenectomy (PD) for adenocarcinoma remains controversial. We analyzed all patients who underwent vascular resection (VR) at the time of PD for any histology ...
  • Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head 
    Varadhachary, Gauri; Wolff, Robert; Crane, Christopher; Sun, Charlotte; Lee, Jeffrey; Pisters, Peter; Vauthey, Jean-Nicolas; Abdalla, Eddie; Wang, Huamin; Staerkel, Gregg; Ross, William; Tamm, Eric; Bhosale, Priya; Krishnan, Sunil; Das, Prajnan; Ho, Linus; Xiong, Henry; Abbruzzese, James; Evans, Douglas (2015-11-17)
    Purpose We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarci ...
  • Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation 
    Katz, Matthew; Varadhachary, Gauri; Fleming, Jason; Wolff, Robert; Lee, Jeffrey; Pisters, Peter; Vauthey, Jean-Nicolas; Abdalla, Eddie; Sun, Charlotte; Wang, Huamin; Crane, Christopher; Lee, Jeffrey; Tamm, Eric; Abbruzzese, James; Evans, Douglas (2015-11-19)
    Purpose The role of carbohydrate antigen (CA) 19-9 in the evaluation of patients with resectable pancreatic cancer treated with neoadjuvant therapy prior to planned surgical resection is unknown. We evaluated CA 19-9 as ...